AKESO(HK:09926) 智通财经网·2025-08-18 07:04Group 1 - 康方生物's stock price increased over 4%, reaching a new high of 173.8 HKD, with a trading volume of 1.212 billion HKD [1] - The 2025 World Lung Cancer Conference (WCLC) will take place in Barcelona, Spain, where 康方生物's partner Summit Therapeutics will present the results of the HARMONi study, a pivotal Phase III clinical trial for the PD-1/VEGF bispecific antibody drug [1] Group 2 - UBS has added 康方生物 to its list of major recommended stocks in the Asia-Pacific region, citing the overseas potential of its main asset, Edafo, which is not fully reflected in the stock price [2] - The firm believes that news regarding potential collaborations with multinational companies and the upcoming HARMONi study results will act as positive catalysts for the stock price [2] - UBS raised its peak sales forecast for Edafo from 14.6 billion USD to 16.3 billion USD and for another key asset, Okan, from 2.2 billion USD to 3.4 billion USD, while increasing the target price from 197.5 HKD to 224.3 HKD with a "Buy" rating [2]